Astrazeneca (AZN) Receivables (2009 - 2026)

Astrazeneca has reported Receivables for 18 years, with the latest figure at $15.7 billion in Q2 2026.

• On a quarterly basis, Receivables rose 2.93% year-over-year to $15.7 billion in Q2 2026; TTM through Jun 2026 was $15.7 billion, a 2.93% increase from a year earlier, with the FY2025 full-year figure at $16.5 billion, up 18.72% from the prior year.
• Receivables was $15.7 billion for Q2 2026 at Astrazeneca, up from $15.3 billion in the prior quarter.
• The five-year high for Receivables was $16.5 billion in Q4 2025, with the low at $9.5 billion in Q1 2022.
• Average Receivables over 5 years is $12.9 billion, with a median of $12.4 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables jumped 41.44% in 2022, then grew 0.08% in 2024.
• Over 5 years, Receivables stood at $11.4 billion in 2022, then rose by 13.85% to $12.9 billion in 2023, then gained by 7.53% to $13.9 billion in 2024, then increased by 18.72% to $16.5 billion in 2025, then slipped by 4.99% to $15.7 billion in 2026.
• The last three Receivables figures came in at $15.7 billion (Q2 2026), $15.3 billion (Q1 2026), and $16.5 billion (Q4 2025), per Business Quant data.